denosumab
daiichi sankyo,amgen
['denosumab']
promising data on denosumab in erosive oa
phase 2 study - less erosive progression, more symptom improvement abs# l05 #acr22 
Rheumatologist. Amateur chef. YNWA. Views and opinions are my own.